Search Results
Aug 06, 2025, 11:30 ET Seeing with fresh eyes: Stowers Scientists establish snails as a system for studying sight restoration
snails not only have pax6 but also that this gene is critical for their eyes to develop," said Accorsi. In the lab, the team optimized the gene-editing technique CRISPR-Cas9 for apple snails that allowed them to disrupt pax6 gene function. The new line of snails was healthy yet noticeably
More news about: Stowers Institute for Medical Research
Aug 06, 2025, 10:30 ET Biopharmaceutical CDMO Market worth US$34.15 billion in 2030 with 8.8% CAGR | MarketsandMarkets™
offers a comprehensive range of services, including the manufacturing of biologic drug substances and products and cGMP manufacturing for cell & gene therapies. Lonza's strong market presence is supported by a wide service portfolio, advanced production facilities, a broad global reach, and continuous
More news about: MarketsandMarkets
Aug 06, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Aug 06, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
action] On May 27, 2025, Rocket issued a press release "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease." The press release disclosed that "[a] patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected
More news about: Pomerantz LLP
Aug 06, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
dystrophy ("DMD"), a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by the mutation of the dystrophin gene, resulting in, inter alia, a limited production of the dystrophin protein, which in turn leads to DMD's clinical features. According to PepGen,
More news about: Pomerantz LLP
Aug 06, 2025, 08:43 ET Excellos, Lonza, and Akadeum Life Sciences Unite to Advance Cell Therapy Manufacturing Through Enhanced Starting Material Quality
manufacturing, and cell separation technology to explore how aligned, modular innovation can streamline workflows and improve outcomes across the cell and gene therapy (CGT) landscape.
More news about: Akadeum Life Sciences
Aug 06, 2025, 03:00 ET Neues Buch verbindet bipolare Störung mit Überlebensmerkmalen der Neandertaler
Neandertaler-Merkmale zurückführt. Shermans Buch verbindet Paläoanthropologie, Genetik und Psychologie, um zu zeigen, dass einige moderne Menschen Neandertaler-Gene in sich tragen, die für zyklische Verhaltensweisen - wie Depressionen und manische Episoden - verantwortlich sind, die einst während der eiszeitlichen
More news about: Julia Sherman
Aug 05, 2025, 16:19 ET Cryoport Reports Second Quarter 2025 Financial Results
platform. "Revenue from the support of commercial cell and gene therapies increased 33% year-over-year to $8.7 million. This growth continues to be fueled by the increasing development and adoption of cell & gene therapies, a positive trend we believe will continue for
More news about: Cryoport, Inc.
Aug 05, 2025, 15:22 ET New National Survey from Automatic Trap Company Shows 88% of Travelers Will Give a 1-Star Rating If a Rodent is Seen at a Vacation Rental Property
public is very aware of the dangers of rodents in living spaces – especially after the national news story of the tragic death of Gene Hackman and Betsy Arakawa. Rodent eradication should be top-of-mind for any Airbnb host." While the most
More news about: Automatic Trap Company
Aug 05, 2025, 15:06 ET DEADLINE APPROACHING: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Inquire About a Securities Fraud Class Action by August 11, 2025
CLICK HERE. Rocket Pharmaceuticals, headquartered in Cranbury, New Jersey, specializes in gene therapies for rare and life-threatening diseases. The lawsuit claims the Company failed to disclose major safety-related updates to its RP-A501
More news about: Berger Montague
Aug 05, 2025, 14:44 ET bioMérieux Develops Game Changing Quality Control Solution GENE-UP® PRO HRM
improving yield. Both GENE-UP® PRO HRM and GENE-UP® PRO ACB are a result of bioMérieux's xPRO™ Program, an innovation engine within bioMérieux that challenges the status quo to advance molecular diagnostics. To learn more about how GENE-UP® PRO HRM, GENE-UP®
More news about: bioMérieux
Aug 05, 2025, 14:08 ET OCI Announces Merger with GMS Piling
consumables from a single trusted partner, supported by rapid order fulfillment and expert technical support." Gene Swindell, founder of GMS, added, "Joining forces with OCI is a natural evolution for GMS. We are excited to combine our capabilities and further
More news about: Grand Valley Holdings, LLC
Aug 05, 2025, 11:44 ET Cell Line and Membrane Market to Grow at 12.5% CAGR Through 2030
further segmented into cancer cell lines, immunotherapy cell lines, ion channel cell lines, cell signalling pathway cell lines, GPCR cell lines and gene knockout cell lines. Applications include basic research, biopharmaceutical production, drug discovery, toxicity testing and tissue engineering. The
More news about: BCC Research LLC
Aug 05, 2025, 10:45 ET Liquid Biopsy Market worth US$7.05 billion by 2030 with 11.8% CAGR | MarketsandMarkets™
Pages By technology, the liquid biopsy market is segmented by technology into multi-gene parallel analysis using NGS and single-gene analysis using PCR & microarrays. In 2024, the multi-gene parallel analysis using NGS segment accounted for the largest share of the market. The large share
More news about: MarketsandMarkets
Aug 05, 2025, 10:45 ET Cell Culture Market to Reach USD 71.1 Billion by 2032, Says SkyQuest Technology Consulting
to emerge as the fastest-growing region for cell culture companies in the long run. High clinical research potential and growing awareness regarding gene, and cell therapies are generating new business scope. China, India, Japan,
More news about: SkyQuest Technology
Aug 05, 2025, 10:07 ET LexisNexis Recognizes Pivot Bio as One of the World's Ten Most Innovative Biotech Startups
encompasses breakthrough innovations in microbial engineering, biological nitrogen fixation, and agricultural application methods. The company's proprietary gene-editing techniques enable naturally occurring soil microbes to continuously produce plant-available nitrogen, even in the presence of synthetic fertilizers
More news about: Pivot Bio, Inc
Aug 05, 2025, 08:57 ET OCI Announces Merger with GMS Piling
drilling consumables from a single trusted partner, supported by rapid order fulfillment and expert technical support." Gene Swindell, founder of GMS, added, "Joining forces with OCI is a natural evolution for GMS. We are excited to combine our capabilities and further
More news about: Gemspring Capital
Aug 05, 2025, 08:45 ET Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact Levi & Korsinsky
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii)
More news about: Levi & Korsinsky, LLP
Aug 05, 2025, 07:00 ET ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine
Sara Deola, M.D., Ph.D., Research Investigator at Sidra Medicine. "We're eager to support the emerging Cell & Gene Therapy (CGT) industry in Qatar and the Middle East. By entering the field of CAR-T
More news about: Bio-Techne Corporation
Aug 05, 2025, 06:30 ET Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance
grew 3% year over year, primarily driven by growth in Next Generation Sequencing, partially offset by a year-over-year decline in Sanger Sequencing and Gene Synthesis.Summary of GAAP Earnings Results - Continuing Operations Operating loss was
More news about: Azenta
Aug 04, 2025, 20:08 ET METiS Technologies Closes RMB 400 Million Series D Financing to Power Beijing's Biopharmaceutical Innovation Engine
enable AccurEdit Therapeutics to develop a liver-targeted CRISPR gene-editing therapy using mRNA-LNP delivery.AccurEdit Therapeutics is a pioneering biotech company developing precise, safe, and effective in vivo gene editing therapies for hereditary and acquired diseases. The company
More news about: METiS Technologies
Aug 04, 2025, 18:03 ET DEADLINE NEXT WEEK: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
11, 2025. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided
More news about: Robbins Geller Rudman & Dowd LLP
Aug 04, 2025, 10:01 ET Cell Culture Market is expected to generate a revenue of USD 93.49 Billion by 2032, Globally, at 14.23% CAGR: Verified Market Research®
Global Cell And Gene Therapy Bioassay Services Market Size By Type of Therapy (Cell Therapy, Gene Therapy), By Test Type (Functional Assays, Cell Proliferation Assays, Cytokine Analysis), By Therapeutic Area
More news about: Verified Market Research
Aug 04, 2025, 09:00 ET Minaris Advanced Therapies Opens New State-of-the-Art GMP Facility to Support Global Cell and Gene Therapy Growth
systems"The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally," said Dr. Orla Cloak, Chief Executive Officer of Minaris Advanced Therapies. "It enhances our European footprint and enhances
More news about: Minaris Advanced Therapies, LLC
Aug 04, 2025, 09:00 ET Minaris Advanced Therapies Opens New State-of-the-Art GMP Facility to Support Global Cell and Gene Therapy Growth
systems"The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally," said Dr. Orla Cloak, Chief Executive Officer of Minaris Advanced Therapies. "It enhances our European footprint and enhances
More news about: Minaris Advanced Therapies, LLC